New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A/F function.
Anella SavianoAdel Abo ManosourFederica RaucciFrancesco MerlinoNoemi MariglianoAnna SchettinoMussarat WahidJenefa BegumAndrew FilerJulia E ManningGian Marco CasilloMarialuisa PiccoloMaria Grazia FerraroSimona MarzanoPasquale RussomannoRosa BellavitaCarlo IraceJussara AmatoMohammed AlfaifiPeter RimmerTariq IqbalStefano PierettiValentina VelleccoFrancesco CasoLuisa CostaRoberto GiacomelliRaffaele ScarpaGiuseppe CirinoMariarosaria BucciHelen M McGettrickPaolo GriecoAsif Jilani IqbalFrancesco MaionePublished in: Annals of the rheumatic diseases (2023)
Collectively, our preclinical and in vitro clinical evidence indicates high efficacy and therapeutic potency of Ab-IPL-IL-17, supporting the rationale for large-scale clinical evaluation of Ab-IPL-IL-17 in patients with IMIDs.
Keyphrases